Lexicon Q2 net income of $3.3M vs loss; licensing revenue from Novo Nordisk drives top line

LEXICON PHARMACEUTICALS, INC.

2025-Q2 EPS reported -$0.06 revenue$30,128,000

Total revenues $28.9M (vs $1.6M Q2'24) driven by $27.5M licensing from Novo Nordisk LX9851 deal.
Net income $3.3M ($0.01 diluted EPS) vs net loss $53.4M ($0.17 loss) in Q2'24.
SG&A expenses fell to $9.4M from $39.2M due to strategic repositioning and reduced INPEFA marketing.
Cash & investments $139M at June 30, 2025, down from $238M at Dec 31, 2024, reflecting severance payments.
Pipeline: pilavapadin partnership talks ongoing; LX9851 IND-enabling on track; SONATA enrollment target for 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.